Drug · CHEMBL822
TERBINAFINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TERBINAFINE. Drugs and targets, record CHEMBL822. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL822
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases12
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 12Source Open Targets
See all 12 diseasesTrials35
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00443820 | Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail | Phase 3 | 526 | 2011-04-19 | terbinafine | Its name | ClinicalTrials.gov |
| NCT00443898 | Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail | Phase 3 | 518 | 2011-04-20 | terbinafine | Its name | ClinicalTrials.gov |
| NCT01433107 | Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis | Phase 3 | 290 | 2013-12-27 | terbinafine | Its name | ClinicalTrials.gov |
| NCT00491764 | A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) | Phase 2 | 218 | 2010-01-28 | terbinafine | Its name | ClinicalTrials.gov |
| NCT01851590 | Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis | Phase 4 | 129 | 2015-11-30 | terbinafine | Its name | ClinicalTrials.gov |
| NCT00833586 | Terbinafine HCl 250 mg Tablet Under Fasting Conditions | Phase 1 | 28 | 2009-08-18 | terbinafine | Its name | ClinicalTrials.gov |
| NCT01145807 | TDT 067 Onychomycosis Study | Phase 3 | 738 | tdt 067 | Its name | ClinicalTrials.gov | |
| NCT05279846 | A Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO) | Phase 3 | 350 | terbinafine | Its name | ClinicalTrials.gov | |
| NCT06369727 | Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design | Phase 1 | 250 | terbinafine | Its name | ClinicalTrials.gov | |
| NCT07382427 | A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails | Phase 2 | 200 | terbinafine | Its name | ClinicalTrials.gov |
1 to 10 of 35
See all 35 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Terbinafine vs Placebo: Number of Subjects With Adverse Event | 9 of 146 | 11 of 144 | 290 | NCT01433107 | Trial comparisons |
| Terbinafine vs Placebo: serious adverse events | 0 of 146 | 0 of 144 | 290 | NCT01433107 | Trial comparisons |
| Terbinafine vs Placebo: Effective Treatment Outcome (Direct Microscopy and Culture Negative and Total Signs and Symptom Score Less or Equal to 2) | 73 of 115 | 10 of 122 | 237 | NCT01433107 | Trial comparisons |
Papers from its trials8
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL822
GET https://conductscience.org/api/drugs/v1/CHEMBL822/trials?page=2